In-Depth

The In-Depth page consists of Insight Articles, Commentaries, C-level Q&As, Discussion Group Reports, and Survey Reports.

Insight Article
Will 3D model development reach its potential to innovate cell and gene therapeutics? We spoke to Merck, GlaxoSmithKline, East Carolina University Brody School of Medicine, and the Institute of Molecular Biotechnology to find out more.
By Tia Byer |
29 April 2022
Tissue Engineering & 3D Models
Discussion Group Report
Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our April Discussion Group addressing ‘3D Model Development’ brought together an exclusive panel of key opinion leaders to address the market’s growth and future directions.
By Tia Byer |
28 April 2022
Tissue Engineering & 3D Models
Commentary
Raymond R. Mattingly explains the applications of 3D cell culturing at Oxford Global’s 3D Cell Culture Symposium.
By Tom Cohen |
24 April 2022
Tissue Engineering & 3D Models
Commentary
This Commentary piece explores how the production and delivery of NK cells could provide a new option for clinical treatment of illnesses such as myeloid leukaemia, with the potential for scaling approaches to be incorporated into the treatment process.
By Ben Norris |
24 March 2022
Cell Therapy Development
Discussion Group Report
Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our February Discussion Group addressing ‘Cell Line Engineering’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.
By Tia Byer |
23 March 2022
Cell Line Development & Engineering
Insight Article
Can the cell and gene therapy field create industry consensus on a more detailed level? In this Insight Article, Jorgen Magnus, Strategic Program Lead of Cell and Gene Therapy at Bayer, highlights the promise of process mapping for reaching a harmonised approach to development and manufacturing standards.
By Tia Byer |
17 March 2022
Gene Therapy Development
Insight Article
Emerging experts in the field of cell therapy: Emily Warner, Moin Saleem, and John Maher, answer questions about their science and industry
07 March 2022
Cell Therapy Development
Insight Article
The need to demonstrate clonality for regulatory approval means that now more than ever, the industry must look towards streamlining and optimising clone selection efficacy. We sat down with senior representatives from Ichnos Sciences and Sanofi to learn how.
By Tia Byer |
28 February 2022
Cell Line Development & Engineering
Discussion Group Report
Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our January Discussion Group addressing ‘Streamlining Stem Cell Manufacturing’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.
By Tia Byer |
03 February 2022
Cell & Gene Therapy Manufacturing
Discussion Group Report
Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our November Discussion Group addressing ‘Advancing The Implementation Of Automation Technologies For Cell Therapy Development’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.
By Tia Byer |
31 January 2022
Cell Therapy Development
Insight Article
Regenerative medicine is a highly promising branch of pharmacology. With the growing demand for stem cell therapies, the need for streamlined manufacturing is more critical than ever. We sat down with senior representatives from Procella Therapeutics, the University of Reading, and Newcastle University to learn more about the future of stem cell production.
By Tia Byer |
29 January 2022
Stem Cell Development & Manufacturing
Commentary
Dr Darius Widera shows us three case studies on 3D stem cell cultivation using fibrin, nanofibrillar cellulose, and hybrid scaffolds
By Tom Cohen |
28 January 2022
Stem Cell Development & Manufacturing
Commentary
This commentary article looks at the future of AAV engineering and cell therapy analytics, with exclusive insights from Sanofi and Genentech.
By Tia Byer |
22 December 2021
Gene Therapy Development
Discussion Group Report
Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our October Discussion Group addressing ‘Challenges and Opportunities in Viral Vector-Based Gene Therapy’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.
By Tia Byer |
09 December 2021
Gene Therapy Development
Insight Article
What will the future of cell culture process development look like? We delve into 3 of the most promising approaches to achieve Next Generation advances for cell and gene therapy.
By Tia Byer |
17 November 2021
Upstream & Downstream Bioprocessing
Commentary
What does the future of the vaccine look like? Tony D’Amore and Yan-Ping Yang of Sanofi Pasteur take us through the ever-evolving vaccine development and manufacturing landscape.
By Tia Byer |
01 November 2021
Cell Therapy Development
Insight Article
What are the key challenges facing gene therapy commercialisation today, and how can the industry best overcome them? This Insight Article delves into the top 3 strategies needed to bring the next generation of advanced therapeutics to the market and get ahead of the game.
By Tia Byer |
22 October 2021
Cell & Gene Therapy Manufacturing
Commentary
Arun Srivastava of the University of Florida’s takes us through the history of the AAV Vector development for Human Gene Therapy and analyses the critical role of his institution’s Division of Cellular and Molecular Therapy in the optimising and discovery of Next Generation AAVs.
By Tia Byer |
07 October 2021
Gene Therapy Development
Insight Article
Commentary piece following conversations with expert speakers from the Cell Series UK 2019
29 October 2019
Cell Therapy Development
Insight Article
Cleo Kontoravdi, Senior Lecturer Imperial, College London
25 October 2018
Cell Therapy Development
Advertisement

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

Member Community Login